Brivanib (BRI) versus Sorafenib (SOR) as First-line Therapy in Patients with Unresectable, Advanced Hepatocellular Carcinoma (HCC): Results from the Phase 3 BRISK-FL Study
Resource
Hepatology, 56(6), 1519-1520
Journal
Hepatology
Journal Volume
56
Journal Issue
6
Pages
1519-1520
Date Issued
2012
Date
2012
Author(s)
Johnson, Phillip
Qin, Shukui
Park, Joong-Won
Poon, Ronnie T.
Raoul, Jean-Luc
Philip, Philip A.
Hsu, Chih-Hung
Hu, Tsung-Hui
Heo, Jeong
Xu, Jianming
Lu, Ligong
Chao, Yee
Boucher, Eveline
Han, Kwang-Hyub
Paik, Seung Woon
Robles-Avina, Jorge
Kudo, Masatoshi
Liu, David
Ezzeddine, Rana
Walters, Ian
Cheng, Ann-Lii
File(s)![Thumbnail Image]()
Loading...
Name
index.html
Size
23.1 KB
Format
HTML
Checksum
(MD5):36c5bd544037f513e91c222edb0ad2f7